| 5/15/2024 | CVLM | Pharming issues clean-up call for 3% convertibles due 2025
|
| 4/19/2024 | CVLM | Pharming repurchases €123.1 million 3% convertibles due 2025
|
| 4/18/2024 | CVLM | Pharming starts tender offer for 3% convertibles due 2025
|
| 4/18/2024 | CV | New Issue: Pharming sells €100 million 4.5% convertibles due 2029, up 37.5%
|
| 1/15/2020 | CV | New Issue: Pharming Group prices €125 million five-year convertible bonds to yield 3%, up 40%
|
| 1/14/2020 | CV | Pharming Group to price €125 million five-year convertible bonds to yield 2.25%-3%, up 35%-40%
|
| 5/16/2017 | HYIG | Market Commentary: Private placement pace thin; Pharming gets $100 million 12% four-year debt facility
|
| 5/16/2017 | BKPV | Pharming gets $100 million 12% four-year senior secured debt facility
|
| 6/15/2015 | PF | Market Commentary: Preferreds rise as equities decline on Greece news; AmTrust Financial frees, weakens
|
| 8/1/2012 | PP | Pharming secures €10 million two-year equity working capital facility
|
| 6/13/2012 | CVLM | Pharming Group redeems final tranche of €8.4 million convertible bond
|
| 2/9/2012 | CVLM | Pharming Group redeems second tranche of €8.4 million convertible bond
|
| 1/6/2012 | CVLM | Pharming Group redeems part of its €8.4 million convertible bond
|
| 7/21/2011 | PP | Pharming Group wraps €3.2 million private placement of stock, warrants
|
| 12/3/2010 | PP | Pharming Group plans €16.1 million non-convertible note placement
|
| 10/12/2010 | CVLM | Pharming: Holders exercise put option for rest of 6.875% convertibles
|
| 9/2/2010 | CVLMPP | Pharming Group converts, clears remaining January 2010 private bonds
|
| 8/18/2010 | CVLM | Pharming plans repayment of remaining 6.875% convertibles due 2012
|
| 6/15/2010 | PP | New Issue: Pharming Group raises €12 million through private placement of stock
|
| 6/15/2010 | PP | Market Commentary: BNC Bancorp settles $35 million; Pharming heralds €12 million sale of stock; Luna closes deal
|
| 5/27/2010 | PP | Market Commentary: Pharming to enter PIPE market; Harte Gold settles tranche; Equatorial Palm to raise £5 million
|
| 5/27/2010 | PP | Pharming Group arranges equity private placement for up to €12 million
|
| 1/5/2010 | PP | New Issue: Pharming Group sells €7.5 million one-year convertibles to yield 9%
|
| 1/5/2010 | PP | Market Commentary: Pharming seeks €7.5 million; Genesis Fluid seals offering; Oragenics closes private stock sale
|
| 10/8/2009 | CV | Pharming cuts convertible debt to €10.9 million in conversion offer
|
| 10/5/2009 | PP | Market Commentary: Pharming lifts SEDA; China Ritar arranges direct placement; IA Global secures equity facility
|
| 10/5/2009 | PP | New Issue: Pharming Group lifts committed equity financing facility to €30 million
|
| 9/30/2009 | CV | Pharming extends conversion offer for 6.875% convertibles to Oct. 13
|
| 6/17/2009 | CV | Pharming Group exchanges €9 million of its convertible debt for shares
|
| 4/15/2009 | PP | New Issue: Pharming Group secures €20 million committed equity financing with Yorkville
|
| 4/15/2009 | PP | Market Commentary: Excellon completes financing; FNX Mining plans C$15 million deal; Panmure secures €20 million
|
| 1/12/2009 | CV | Pharming buys back €5 million 6.875% convertibles
|
| 12/31/2008 | CV | Pharming in discussions for more redemptions, conversions of convertible loan notes
|
| 12/8/2008 | CV | Pharming bondholders agree to cancellation of €20.1 million 6.875% convertibles
|
| 10/27/2006 | BT | Pharming ends Q3 with 75% more cash, net loss hits €4.4 million
|
| 8/17/2006 | BT | Pharming seeks EMEA approval for Rhucin for attacks of hereditary angioedema
|
| 8/10/2006 | BT | Pharming says it will proceed with acquisition of Dnage
|
| 8/4/2006 | BT | Pharming's six-month net loss improves slightly to €8.1 million
|
| 7/28/2006 | BT | Pharming receives fast-track status for recombinant human C1 inhibitor
|
| 7/21/2006 | BT | Pharming seeks marketing authorization for recombinant human C1 inhibitor in Europe
|
| 6/29/2006 | BT | Pharming awarded patent for human C1 inhibitor
|
| 6/14/2006 | BT | Pharming gets orphan-drug status for rhC1INH for two transplant-related disorders
|
| 5/16/2006 | BT | Pharming Group, DSM to participate in Dutch BioMedical Materials consortium
|
| 3/24/2006 | BT | Pharming to acquire outstanding shares of biotechnology company DNage
|
| 2/24/2006 | BT | Pharming: Phase 3 trials of rhC1INH to treat hereditary angioedema look positive
|
| 2/17/2006 | BT | Pharming says 2005 loss widened to €17.9 million, revenue fell
|
| 2/3/2006 | BT | Pharming receives $30 million for angioedema drug development
|
| 1/25/2006 | BTPP | New Issue: Pharming Group wraps €17.1 million private placement of stock
|
| 12/30/2005 | BT | Pharming files GRAS notification with FDA for human lactoferrin
|
| 11/17/2005 | BT | Pharming Group studies show rhC11nH inhibitor brings rapid relief to angioedema patients
|
